中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2014年
11期
38-39
,共2页
糖尿病肾病%吡格列酮片%前列地尔%尿白蛋白排泄率
糖尿病腎病%吡格列酮片%前列地爾%尿白蛋白排洩率
당뇨병신병%필격렬동편%전렬지이%뇨백단백배설솔
Diabetic nephropathy%Pioglitazone%Alprostadil needle%Urinary albumin excretion rate
目的:观察吡格列酮联合前列地尔治疗早期糖尿病肾病的临床疗效。方法:64例早期糖尿病肾病随机分为治疗组、对照组各32例,在常规治疗基础上,治疗组加用吡格列酮30mg/次,1次/日口服,连服12周;静脉注射前列地尔10μg,1次/日,连续14天,停用2周后再用14天,反复3次至12周。对照组不给上述治疗。观察治疗前后尿白蛋白排泄率(UAER)、尿素氮(BUN)、血肌酐(Scr)、内生肌酐清除率(Ccr)、高敏 C 反应蛋白(hsCRP)、糖化血红蛋白(HbA1c)的变化。结果:治疗组12周后与治疗前比较,UAER、hsCRP、HbA1c明显下降,差异有统计学意义;两组治疗后比较,差异有统计学意义;但两组治疗前后BUN、Scr、Ccr差异无统计学意义。结论:吡格列酮联合前列地尔能减低早期糖尿病肾病的 UREA,并有显著减低血糖及 C 反应蛋白的作用,对缓解糖尿病肾病的发生、发展有重要意义,对早期糖尿病肾病患者临床疗效满意。用药后半年随访无明显增高。
目的:觀察吡格列酮聯閤前列地爾治療早期糖尿病腎病的臨床療效。方法:64例早期糖尿病腎病隨機分為治療組、對照組各32例,在常規治療基礎上,治療組加用吡格列酮30mg/次,1次/日口服,連服12週;靜脈註射前列地爾10μg,1次/日,連續14天,停用2週後再用14天,反複3次至12週。對照組不給上述治療。觀察治療前後尿白蛋白排洩率(UAER)、尿素氮(BUN)、血肌酐(Scr)、內生肌酐清除率(Ccr)、高敏 C 反應蛋白(hsCRP)、糖化血紅蛋白(HbA1c)的變化。結果:治療組12週後與治療前比較,UAER、hsCRP、HbA1c明顯下降,差異有統計學意義;兩組治療後比較,差異有統計學意義;但兩組治療前後BUN、Scr、Ccr差異無統計學意義。結論:吡格列酮聯閤前列地爾能減低早期糖尿病腎病的 UREA,併有顯著減低血糖及 C 反應蛋白的作用,對緩解糖尿病腎病的髮生、髮展有重要意義,對早期糖尿病腎病患者臨床療效滿意。用藥後半年隨訪無明顯增高。
목적:관찰필격렬동연합전렬지이치료조기당뇨병신병적림상료효。방법:64례조기당뇨병신병수궤분위치료조、대조조각32례,재상규치료기출상,치료조가용필격렬동30mg/차,1차/일구복,련복12주;정맥주사전렬지이10μg,1차/일,련속14천,정용2주후재용14천,반복3차지12주。대조조불급상술치료。관찰치료전후뇨백단백배설솔(UAER)、뇨소담(BUN)、혈기항(Scr)、내생기항청제솔(Ccr)、고민 C 반응단백(hsCRP)、당화혈홍단백(HbA1c)적변화。결과:치료조12주후여치료전비교,UAER、hsCRP、HbA1c명현하강,차이유통계학의의;량조치료후비교,차이유통계학의의;단량조치료전후BUN、Scr、Ccr차이무통계학의의。결론:필격렬동연합전렬지이능감저조기당뇨병신병적 UREA,병유현저감저혈당급 C 반응단백적작용,대완해당뇨병신병적발생、발전유중요의의,대조기당뇨병신병환자림상료효만의。용약후반년수방무명현증고。
Objective:To observe the clinical effect of pioglitazone combined with alprostadil in the treatment of early diabetic nephropathy.Methods:64 patients with early diabetic nephropathy were randomly divided into the treatment group and the control group with 32 cases in each.On the basis of conventional therapy,the treatment group added pioglitazone 30mg/time,1 time/day orally for 12 weeks;the treatment group added alprostadil 10μg for intravenous injection,1 time/day,for 14 consecutive days,the drug was used again for 14 days at 2 weeks after drug withdrawal,this method was repeated 3 times until 12 weeks.The control group was not given the treatment.The changs of urinary albumin excretion rate(UAER),blood urea nitrogen(BUN),serum creatinine(Scr),creatinine clearance rate(Ccr),high sensitive C reactive protein(hsCRP),glycosylated hemoglobin(HbA1c) before and after treatment were observed.Results:Compared with before treatment,at 12 weeks after treatment,UAER,hsCRP and HbA1c were decreased significantly,the difference was statistically significant;compared the two groups after treatment,the difference was statistically significant;but BUN,Scr and Ccr of the two groups before and after treatment were no significant difference.Conclusion:Pioglitazone combined with alprostadil can reduce UREA of the early diabetic nephropathy.It has the function of significantly reducing blood glucose and C reactive protein,and has important significance for alleviating the incidence of diabetic nephropathy. The clinical curative effects of patients with early diabetic nephropathy is satisfactory.In the follow-up of half a year later after treatment,there is no significant increase.